Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
Abstract Objective This study aimed to assess the safety and efficacy of generic nab-paclitaxel in the Chinese population in a real-world setting. Methods This prospective, multicenter, observational study enrolled patients with malignancies who received any generic nab-paclitaxel-based regimens in...
Saved in:
| Main Authors: | Fei He, Yancai Sun, Wenzhou Zhang, Qiongshi Wu, Donghang Xu, Zaixian Bai, Zhiying Hao, Weiyi Feng, Kanghuai Zhang, Jiang Liu, Mei Dong, Guangxuan Liu, Guohui Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01609-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01) -
Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags
by: Helen Linxweiler, et al.
Published: (2024-10-01) -
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01) -
Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
by: Lenka N.C. Boyd, et al.
Published: (2024-09-01) -
Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel
by: Soumen Saha, et al.
Published: (2024-11-01)